HK1153938A1 - Use of a cdk inhibitor for the treatment of glioma cdk - Google Patents

Use of a cdk inhibitor for the treatment of glioma cdk

Info

Publication number
HK1153938A1
HK1153938A1 HK11108251.4A HK11108251A HK1153938A1 HK 1153938 A1 HK1153938 A1 HK 1153938A1 HK 11108251 A HK11108251 A HK 11108251A HK 1153938 A1 HK1153938 A1 HK 1153938A1
Authority
HK
Hong Kong
Prior art keywords
cdk
glioma
treatment
inhibitor
cdk inhibitor
Prior art date
Application number
HK11108251.4A
Other languages
English (en)
Chinese (zh)
Inventor
．塞歐梅
．法歐倫逖尼
．派森逖
Original Assignee
內爾維阿諾醫學科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 內爾維阿諾醫學科學有限公司 filed Critical 內爾維阿諾醫學科學有限公司
Publication of HK1153938A1 publication Critical patent/HK1153938A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK11108251.4A 2008-07-29 2011-08-08 Use of a cdk inhibitor for the treatment of glioma cdk HK1153938A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161323 2008-07-29
PCT/EP2009/059747 WO2010012733A1 (en) 2008-07-29 2009-07-28 Use of a cdk inhibitor for the treatment of glioma

Publications (1)

Publication Number Publication Date
HK1153938A1 true HK1153938A1 (en) 2012-04-13

Family

ID=41060058

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11108251.4A HK1153938A1 (en) 2008-07-29 2011-08-08 Use of a cdk inhibitor for the treatment of glioma cdk

Country Status (7)

Country Link
US (1) US8946226B2 (de)
EP (1) EP2323664B1 (de)
JP (1) JP5677296B2 (de)
CN (1) CN102105151B (de)
ES (1) ES2532732T3 (de)
HK (1) HK1153938A1 (de)
WO (1) WO2010012733A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2738026C (en) 2008-09-22 2017-01-24 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
DK3106463T6 (da) 2008-10-22 2020-02-24 Array Biopharma Inc Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer
EP2376084B1 (de) * 2008-11-24 2013-07-17 Nerviano Medical Sciences S.r.l. CDK-Inhibitor zur Behandlung von Mesotheliom
US8586598B2 (en) * 2009-04-29 2013-11-19 Nerviano Medical Sciences S.R.L. CDK inhibitor salts
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
HUE035337T2 (en) 2010-05-20 2018-05-02 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
WO2012101032A1 (en) * 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
EP2668188B1 (de) * 2011-01-26 2016-05-18 Nerviano Medical Sciences S.r.l. Tricyclische derivate, verfahren zu ihrer herstellung und ihre verwendung als kinasehemmer
CN104427984A (zh) 2012-01-20 2015-03-18 D·布朗 包括二脱水半乳糖醇和类似物的经取代的己糖醇类于治疗包括多形性胶质母细胞瘤和成神经管细胞瘤的肿瘤疾病和癌症干细胞的用途
CA2894948C (en) * 2012-12-20 2022-07-19 Lantmannen As-Faktor Ab Use of antisecretory factor (af) in glioblastoma treatment
DK3699181T3 (da) 2014-11-16 2023-03-20 Array Biopharma Inc Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
EA201792679A1 (ru) 2015-06-01 2018-06-29 Локсо Онколоджи, Инк. Способы диагностики и лечения злокачественной опухоли
EP3322706B1 (de) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituierte pyrazol[1,5-a]pyridin-verbindungen als ret-kinasehemmer
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
PE20181888A1 (es) 2016-04-04 2018-12-11 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
MA44612A (fr) 2016-04-04 2019-02-13 Loxo Oncology Inc Méthodes de traitement de cancers pédiatriques
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
EP3800189B1 (de) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Herstellung von (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
ES2923415T3 (es) * 2017-08-11 2022-09-27 Shengke Pharmaceuticals Jiangsu Ltd Compuesto de 1H-pirazolo[4,3-H]quinazolina que sirve como inhibidor de proteína quinasa
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (de) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituierte pyrrolo[2,3-d]pyrimidinverbindungen als ret-kinase-inhibitoren
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
CN113490666A (zh) 2018-12-19 2021-10-08 奥瑞生物药品公司 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20094664B (en) * 2003-05-22 2009-04-10 Nerviano Medical Sciences Srl Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
US8084027B2 (en) * 2006-02-10 2011-12-27 Nerviano Medical Sciences S.R.L. Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic
US8518930B2 (en) * 2008-07-29 2013-08-27 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent
EP2376084B1 (de) * 2008-11-24 2013-07-17 Nerviano Medical Sciences S.r.l. CDK-Inhibitor zur Behandlung von Mesotheliom

Also Published As

Publication number Publication date
WO2010012733A1 (en) 2010-02-04
CN102105151B (zh) 2013-12-18
JP5677296B2 (ja) 2015-02-25
EP2323664B1 (de) 2015-01-07
WO2010012733A9 (en) 2011-04-14
JP2011529467A (ja) 2011-12-08
EP2323664A1 (de) 2011-05-25
US20110190311A1 (en) 2011-08-04
CN102105151A (zh) 2011-06-22
US8946226B2 (en) 2015-02-03
ES2532732T3 (es) 2015-03-31

Similar Documents

Publication Publication Date Title
HK1153938A1 (en) Use of a cdk inhibitor for the treatment of glioma cdk
HUS1800011I1 (hu) Kombinációs terápia szubsztituált oxazolidinonokkal
HK1214514A1 (zh) 神經浸潤抑制劑
ZA201004859B (en) Use of a gamma-secretase inhibitor for treating cancer
HK1208237A1 (en) Methods for the treatment of gout
EP2026843A4 (de) Therapeutische verwendungen von rtp801l
IL193484A0 (en) Gsk-3 inhibitors for the treatment of osteoporosis
EP2195010A4 (de) Behandlung mit kallikrein-inhibitoren
EP2272817A4 (de) Pai-1-hemmer
EP2195011A4 (de) Behandlung mit kallikrein-inhibitoren
GB0823480D0 (en) Devices for the treatment of fluids
EP2139475A4 (de) Verwendung des pde7-hemmers zur behandlung von bewegungsstörungen
HK1169408A1 (en) Cdk inhibitor salts cdk
EP2237793A4 (de) Cathepsin-b-hemmer
EP2326318A4 (de) Sur1-hemmer für therapeutische zwecke
ZA201008192B (en) A phytosystem for treatment of sewage
HK1166795A1 (en) Use of a kinase inhibitor for the treatment of thymoma
ZA201103576B (en) Hsp90 inhibitors for therapeutic treatment
ZA201101303B (en) Kit for the treatment of onychomycosis
IL211189A0 (en) Compounds for the treatment of peripheral neuropathies
IL207247A0 (en) Use of ranolazine for the treatment of cardiovascular disease
IL243809A0 (en) Process for the production of γ-ketosulfide compound and γ-ketosulfide compounds
EP2177529A4 (de) Neuer sekretasehemmer
IL203599A (en) Mark @ for treatment @ inhibitor @ of @ egfr
EP2459507A4 (de) Verwendung von erythritol zur verhinderung oder behandlung von hypertonie